Graphique Historique de l'Action
6 Mois : De Avr 2019 à Oct 2019
By Maria Armental
Sanofi's dengue vaccine was approved in the U.S., the first vaccine cleared to treat the mosquito-borne virus in the country and U.S. territories like Puerto Rico, U.S. Virgin Islands, American Samoa and Guam.
The vaccine, Dengvaxia, was approved by the Food and Drug Administration to treat those aged 9 through 16, against the mosquito-borne virus.
The disease is complex to vaccinate against because it can be caused by four different strains of the same virus. Dengvaxia, first approved in Mexico in 2015, targets the four strains; but health regulators warn that it should only be given to those who have previously had a dengue infection, and live in areas where dengue is endemic.
Those who haven't had a previous dengue infection face a higher risk of contracting severe dengue when vaccinated with Dengvaxia.
It is unknown whether Dengvaxia is safe or protective for people living in areas where dengue isn't endemic or who travel to dengue endemic areas, the FDA said.
Write to Maria Armental at firstname.lastname@example.org
(END) Dow Jones Newswires
May 01, 2019 19:23 ET (23:23 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.